HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol

Abstract : One-third of patients aged ≤60 years with aggressive lymphoma are at low-intermediate risk (LIR). Before the rituximab era, we prospectively compared ACVBP with ECVBP, a similar regimen including epirubicin instead of doxorubicin and increased dose intensity of cyclophosphamide, followed by conventional consolidation with an increased amount and dose intensity of cytosine-arabinoside, methotrexate, etoposide, and ifosfamide, in 652 patients with LIR aggressive lymphoma. The overall response rate, 5-year event-free survival (EFS), and survival were estimated to be 86%, 60%, and 74%, respectively, with no differences between the two arms. In patients with diffuse large B-cell lymphoma (DLBCL) who received ACVBP, the 5-year EFS and survival were estimated at 69% and 82%. These findings do not support the use of a chemotherapy regimen more intensive than ACVBP in patients aged ≤60 years with LIR aggressive lymphoma. The results in the control arm, without rituximab, have led to a randomized comparison of R-ACVBP and R-CHOP in this patient population.
Document type :
Journal articles
Complete list of metadata

https://hal-ens-lyon.archives-ouvertes.fr/ensl-00817207
Contributor : Agnès Ganivet Connect in order to contact the contributor
Submitted on : Wednesday, April 24, 2013 - 9:56:07 AM
Last modification on : Tuesday, December 7, 2021 - 4:10:48 PM

Identifiers

  • HAL Id : ensl-00817207, version 1

Citation

Pierre Morel, Jean-Nicolas Munck, Bertrand Coiffier, Christian Gisselbrecht, Dana Ranta, et al.. Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol. Leukemia & lymphoma, Taylor & Francis, 2010, 51 (9), pp.1668-1677. ⟨ensl-00817207⟩

Share

Metrics

Record views

116